MILREM-ROBOTICS
A consortium led by Milrem Robotics and composed of several major defence, communication and cybersecurity companies and high technology SMEs was awarded 30,6 MEUR from the European Commission’s European Defence Industrial Development Programme (EDIDP) to develop a European standardized unmanned ground system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200616005680/en/
During the project, a modular and scalable architecture for hybrid manned-unmanned systems will be developed to standardize a European wide ecosystem for aerial and ground platforms, command, control and communication equipment, sensors, payloads, and algorithms. The prototype system will utilize an existing unmanned ground vehicle – Milrem Robotics’ THeMIS – and a specific list of payloads.
The outcome of the project will be demonstrated in operational environments and relevant climatic conditions as part of participating member states military exercises or at separate testing grounds.
The total cost of the project, titled iMUGS (integrated Modular Unmanned Ground System), is 32,6 million euros of which 30,6 million will be provided by the European Commission.
“Robotic and autonomous systems will tremendously enhance defence and military capabilities in the coming years all around the world. iMUGS is an excellent example of how Europe can utilize and develop high-end technologies as a joint effort while avoiding scattering activities and resources,” said Kuldar Väärsi, CEO of Milrem Robotics.
“It is nice to see, that the European Defence Fund is efficiently consolidating the requirements of EU member states and the European industry’s capabilities to increase defence capabilities and strategic autonomy. The European industry is determined and ready to provide efficient and deployable technologies already over the next three years in the course of this project,” Väärsi added.
The project is led by Estonia and its technical requirements have also been agreed with Finland, Latvia, Germany, Belgium, France, and Spain who are planning on financing the remaining 2 MEUR of the projects budget.
During the project operational know-how will be gathered and concepts for the combined engagement of manned and unmanned assets developed, while considering the ethical aspects applicable to robotics, artificial intelligence, and autonomous systems. State-of-the-art virtual and constructive simulation environments will also be set up.
iMUGS will be a cooperation between 14 parties: Milrem Robotics (project coordinator), GT Cyber Technologies, Safran Electronics & Defense, NEXTER Systems, Krauss-Maffei Wegmann, Diehl Defence, Bittium Wireless, Insta DefSec, (Un)Manned, dotOcean, Latvijas Mobilais Telefons, GMV Aerospace and Defence, the Estonian Military Academy and Royal Military Academy of Belgium.
Background
The objectives of the EDIDP programme are to contribute to the strategic autonomy of the European Union and to strengthen the cooperation between Member States. The priorities include enabling high-end operations of military forces with special focus on intelligence and secured communications and cyber. Actions include development of next generation ground combat capabilities and solutions in Artificial Intelligence, Virtual Reality and Cyber technologies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005680/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
QPS Selects Oracle Argus Safety Database to Enhance Pharmacovigilance in Clinical Trials15.1.2026 13:57:00 CET | Press release
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/ Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC. The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements. “Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Dere
InterAx and Alveus Announce Strategic Research and Licensing Agreement to Develop Differentiated Therapeutic Candidate for Metabolic Disease15.1.2026 13:30:00 CET | Press release
InterAx Biotech Ltd (“InterAx”) and Alveus Therapeutics Inc. (“Alveus”) today announced a strategic research collaboration and licensing agreement to develop a differentiated small molecule candidate for metabolic disease to deliver durable weight loss with superior tolerability. This partnership forms a joint research effort on a target and modality of established but untapped therapeutic interest by combining InterAx’s Deep Signal™ discovery platform – designed to optimize candidates toward superior signaling profiles – with Alveus’s deep R&D expertise and leadership in obesity, diabetes, and cardiometabolic disease. While financial terms remain undisclosed, the agreement includes an upfront payment and eligibility for future development, regulatory, and commercial milestones. “We are thrilled to join forces with Alveus to advance a highly differentiated therapeutic candidate designed to overcome the limitations of today’s obesity medications,” said Andrew Roberts, CEO of InterAx. “O
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness15.1.2026 13:01:00 CET | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the closing of its previously disclosed strategic collaboration with Zydus Lifesciences Ltd. The agreement is designed to accelerate global development and potential commercialization of Agenus’ botensilimab and balstilimab (BOT+BAL) immunotherapy combination program. The collaboration provides Agenus with strategic capital and committed, long-term biologics manufacturing capacity in the United States to support BOT+BAL clinical development, authorized early access pathways, and commercial supply preparation. As part of the collaboration, Agenus has granted Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka, with Agenus eligible to receive royalties on net sales in those territories. The collaboration, first announced on June 3, 2025, included the following key financial terms: Upfront Consideration: $75 million cash payment to Agenus for transfer of biologics manufac
WHOOP and Samuel Ross MBE Announce Multiyear, Global Creative Partnership, Introducing a New Era in Performance Fashion15.1.2026 13:00:00 CET | Press release
The WHOOP x SR_A collaboration ushers in a new frontier of performance accessories, apparel, and design-driven technology WHOOP, the human performance company, announces a landmark creative partnership with acclaimed designer Samuel Ross MBE, who joins as Global Creative Director, WHOOP x SR_A to lead a multiyear collaboration between the two brands titled PROJECT TERRAIN. The collaboration signals the ongoing evolution of WHOOP from a pioneering wearable technology company into a brand shaping not just the future of personal health but also its intersection with performance fashion and cultural design. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115643104/en/ WHOOP and Samuel Ross MBE Announce Multiyear, Global Creative Partnership, Introducing a New Era in Performance Fashion As the first performance design collaboration for WHOOP, the partnership represents a new chapter for the brand. Under Ross’ direction, PROJECT
TNG Digital and EPOS Launch EPOS360 and EPOS360 BlueTap in Malaysia to Help Local SMEs Grow with AI and Unique Payment Capabilities15.1.2026 11:23:00 CET | Press release
EPOS360, an industry-first all-in-one digital and payments solution, launches as a mini-programme within TNG eWallet, enabling Malaysian SMEs to easily access AI-powered growth tools to engage over 25 million TNG eWallet usersTNG Digital introduces EPOS360 BlueTap, Malaysia’s first tap-to-pay experience using TNG eWalletThrough EPOS, Ant International will make significant strides to empower SME digitalisation, leading the charge for its SME inclusion and growth strategy TNG Digital Sdn. Bhd. (“TNG Digital”), the operator of Malaysia’s leading digital financial services and lifestyle app, TNG eWallet, and EPOS, the all-in-one SME transformation platform of Ant International, have jointly announced the launch of EPOS360 in Malaysia, with a suite of AI-powered growth tools and unique payment capabilities to support the digitalisation of Malaysian businesses, particularly SMEs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom